Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/0011—Cancer antigens
  • A61K39/001169—Tumor associated carbohydrates
  • A61K39/001173—Globo-H
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/0011—Cancer antigens
  • A61K39/00118—Cancer antigens from embryonic or fetal origin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
  • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
  • A61K2039/6031—Proteins
  • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
  • A61K2039/6031—Proteins
  • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
  • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Definitions

• Globo H is a cancer antigen overly expressed in various epithelial cancers. It has been suggested that this antigen can serve as a target in cancer immunotherapy. While vaccines have been developed to elicit antibody responses against Globo H, their anti-cancer efficacies are unsatisfactory due to low antigenecity of Globo H.5 There is a need for a new vaccine capable of eliciting high levels of immune responses targeting Globo H.
• the present invention is based on an unexpected discoveries that (1) SSEA3, o the immediate precursor of Globo H, is expressed at a high level in breast cancer stem cells and therefore can serve as a suitable target for breast cancer treatment, and (2) ⁇ -galactosyl-ceramide ( ⁇ -GalCer) is an effective adjuvant that promotes production of anti-Globo H and anti-SSEA3 antibodies.
• one aspect of this invention features an immune composition 5 containing Globo H or its fragment (e.g., SSEA3) and an adjuvant (e.g., ⁇ -GalCer).
• Globo H or its fragment e.g., SSEA3
• an adjuvant e.g., ⁇ -GalCer
• Globo H or its fragment can be conjugated with Keyhole Limpet Hemocyanin (KLH).
• KLH Keyhole Limpet Hemocyanin
• this immune composition elicits immune responses (e.g., antibody production) targeting Globo H or its fragment and, therefore, is effective in treating cancer (e.g., breast cancer, prostate cancer, ovarian o cancer, and lung cancer).
• cancer e.g., breast cancer, prostate cancer, ovarian o cancer, and lung cancer.
• Another aspect of this invention relates to a method of producing antibody specific to Globo H or its fragment by administering to a non-human mammal (e.g., mouse, rabbit, goat, sheep, or horse) the immune composition described above and isolating from the mammal antibody that binds to Globo H or its fragment.
• a non-human mammal e.g., mouse, rabbit, goat, sheep, or horse
• this invention features a method of treating cancer with a first agent that inhibits the activity of 2-fucosyltransferase 1 (FUTl) or 2-fucosyltransferase 2 (FUT2). Both FUTl and FUT2 are involved in Globo H biosynthesis.
• This agent can be an antibody that blocks the interaction between FUT1IFUT2 and its substrate or an interfering RNA (e.g., siFUTl or siFUT2) that suppresses expression of FUTl or FUT2.
• the first agent, targeting FUTl can be combined with a second agent that inhibits the activity of FUT2.
• the first agent is siFUTl and the second agent is siFUT2.
• the immune composition or the first and second agents in treating cancer and in manufacturing a medicament for the treatment of cancer.
• Fig.l is a diagram depicting the structures of the hexasaccharide epitope in
• Panel A the structure of the hexasaccharide epitope.
• Panel B the structures of the hexasaccharide epitopes and its seven fragments.
• Fig. 2 is a chart showing the levels of anti-Globo H and anti-SSEA3 antibodies in mice immunized with KLH-conjugated Globo H alone and with KLH-conjugated
• Fig. 3 is a diagram showing the effects of siFUTl and siFUT2 on FUTl and FUT2 expression in breast cancer cells.
• Panel A suppression of FUTl expression by siFUTl in MB157 cells.
• Panel B suppression of FUTl and FUT2 expression by siFUTl and siFUT2, respectively, in T-47D cells.
• Fig. 4 is a diagram showing the effects of siFUTl and siFUT2 on inhibiting growth of breast cancer xenografts.
• Panel a a chart showing that siFUTl and siFUT2 inhibited breast tumor growth.
• Panel b a chart showing that siFUTl and siFUT2 reduced weights of tumor mass.
• Globo H and its immediate precursor S SE A3 both can serve as targets in cancer treatment.
• one embodiment of this invention is a method of treating cancer0 by administering to a subject in need thereof an effective amount of an immune composition containing either Globo H or a fragment thereof (e.g., SSEA3, also known as Gb5) and an adjuvant.
• an immune composition containing either Globo H or a fragment thereof (e.g., SSEA3, also known as Gb5) and an adjuvant.
• target cancer include, but are not limited to, breast cancer (including stages 1-4), lung cancer (e.g., small cell lung cancer), liver cancer (e.g., hepatocellular carcinoma and cohlagiocarcinoma), oral5 cancer, stomach cancer (including T1-T4), colon cancer, nasopharynx cancer, skin cancer, kidney cancer, brain tumor (e.g., astrocytoma, glioblastoma multiforme, and meningioma), prostate cancer, ovarian cancer, cervical cancer, bladder cancer, and endometrium, rhabdomyosarcoma, osteosarcoma, leiomyosarcoma, and gastrointestinal stromal tumor.
• breast cancer including stages 1-4
• lung cancer e.g., small cell lung cancer
• liver cancer e.g., hepatocellular carcinoma and cohlagiocarcinoma
• oral5 cancer e.g., hepatocellular carcinoma and cohlagiocarcinoma
• stomach cancer including
• treating refers to the o application or administration of a composition including one or more active agents to a subject, who has cancer, a symptom of cancer, or a predisposition toward cancer, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the cancer, the symptoms of the cancer, or the predisposition toward the cancer.
• An effective amount refers to the amount of each active agent 5 required to confer therapeutic effect on the subject, either alone or in combination with one or more other active agents. Effective amounts vary, as recognized by those skilled in the art, depending on route of administration, excipient usage, and co-usage with other active agents.
• the immune composition used in the above-described method can contain a o glycan (i.e., a molecule containing a sugar moiety) that is Globo H or a fragment thereof and an adjuvant.
• Globo H is a glycan containing the hexasaccharide epitope shown in Fig. 1, Panel A, and optionally, a non-sugar moiety.
• Its fragment is a glycan containing a fragment of the hexasaccharide epitope and, if applicable, the non-sugar moiety. Fragments of the hexasaccharide epitope are shown in Fig. 1, Panel B.
• These oligosaccharides can be prepared by routine methods. See, e.g., Huang et al, Proc. Natl. Acad. Sci. USA 103 : 15-20 (2006). If desired, they can be linked to a non-sugar moiety.
• any of the glycans described above can be conjugated to a protein carrier, such as KLH. They can then be mixed with an adjuvant and optionally a pharmaceutically acceptable carrier (e.g., a phosphate buffered saline, or a bicarbonate solution) to form an immune composition (e.g., a vaccine) via conventional methods.
• a pharmaceutically acceptable carrier e.g., a phosphate buffered saline, or a bicarbonate solution
• the composition may be prepared as injectables, as liquid solutions, or emulsions and the carrier is selected on the basis of the mode and route of administration, as well as on the basis of standard pharmaceutical practice.
• the immune composition preferably contains ⁇ -GalCer as an adjuvant.
• adjuvant include, but are not limited to, a cholera toxin, Escherichia coli heat-labile enterotoxin (LT), liposome, immune-stimulating complex (ISCOM), or immunostimulatory sequences oligodeoxynucleotides (ISS-ODN).
• the composition can also include a polymer that facilitates in vivo delivery. See Audran R. et al. Vaccine 21 :1250-5, 2003; and Denis-Mize et al. Cell Immunol, 225:12-20, 2003. When necessary, it can further contain minor amounts of auxiliary substances such as wetting or emulsifying agents, or pH buffering agents to enhance the ability of the composition to elicit immune responses against the sugar moiety in
• the immune composition described herein can be administered parenterally (e.g., intravenous injection, subcutaneous injection or intramuscular injection).
• parenterally e.g., intravenous injection, subcutaneous injection or intramuscular injection.
• binders and carriers may include, for example, polyalkalene glycols or triglycerides.
• Oral formulations may include normally employed incipients such as, for example, pharmaceutical grades of saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of the immune composition described herein.
• the immune composition is administered in a manner compatible with the dosage formulation, and in an amount that is therapeutically effective, protective and immunogenic.
• the quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize antibodies, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations.
• the dosage of the vaccine may also depend on the route of administration and varies according to the size of the host.
• the immune composition of this invention can also be used to generate antibodies in animals for production of antibodies, which can be used in both cancer treatment and diagnosis.
• Methods of making monoclonal and polyclonal antibodies and fragments thereof in animals are well known in the art. See, for example, Harlow and Lane, (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York.
• the term "antibody” includes intact immunoglobulin molecules as well as fragments thereof, such as Fab, F(ab') 2 , Fv, scFv (single chain antibody), and dAb (domain antibody; Ward, et. al. (1989) Nature, 341, 544).
• Another embodiment of this invention is a method of treating cancer by inhibiting the activity of FUTl and/or FUT2, both being responsible for Globo H biosynthesis.
• FUTl and FUT2 are well-known 2-fucosyltransferases that transfer a fucose unit to the reducing end of an oligosaccharide substrate via an ⁇ 1,2 linkage. See, e.g., NCBI Gene ID:2523 and NCBI Gene ID:2524.
• the just-described method is performed by administering to a subject in need thereof an effective amount of an antibody that interferes with the interaction between FUT1IFUT2 and their substrate, i.e., an antibody specific to FUT1IFUT2 or their substrate.
• FUT1IFUT2 a fragment thereof, or a substrate thereof can be coupled to a carrier protein (e.g., KLH), if necessary, mixed with an adjuvant, and then injected into a host animal.
• a carrier protein e.g., KLH
• Antibodies produced in the animal can then be purified by conventional methods, e.g., affinity chromatography.
• Commonly employed host animals include rabbits, mice, guinea i o pigs, and rats.
• adjuvants that can be used to increase the immunological response depend on the host species and include Freund's adjuvant (complete and incomplete), mineral gels such as aluminum hydroxide, CpG, surface-active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol.
• Useful human adjuvants include
• Monoclonal antibodies, homogeneous populations of antibodies to FUT1IFUT2 or their substrate can be prepared using standard hybridoma technology (see, for example, Kohler et al. (1975) Nature 256,
• monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture such as described in Kohler et al. (1975) Nature 256, 495 and U.S.
• Patent No. 4,376,110 the human B-cell hybridoma technique (Kosbor et al. (1983)
• Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof.
• the hybridoma producing the monoclonal antibodies of the invention may be cultivated in vitro or in vivo.
• the ability to produce high titers of monoclonal antibodies in vivo makes it a particularly useful method of production.
• techniques developed for the production of "chimeric antibodies" can be used. See, e.g., Morrison et al. (1984) Proc. Natl. Acad. Sci. USA 81, 6851; Neuberger et al. (1984) Nature 312, 604; and Takeda et al. (1984) Nature 314:452.
• a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region.
• techniques described for the production of single chain antibodies can be adapted to produce a phage library of single chain Fv antibodies.
• Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge.
• antibody fragments can be generated by known techniques.
• such fragments include, but are not limited to, F(ab') 2 fragments that can be produced by pepsin digestion of an antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab')2 fragments.
• Antibodies can also be humanized by methods known in the art. For example, monoclonal antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland; and Oxford Molecular, Palo Alto, Calif). Fully human antibodies, such as those expressed in transgenic animals are also features of the invention. See, e.g., Green et al. (1994) Nature Genetics 7, 13; and U.S. Patent Nos. 5,545,806 and 5,569,825.
• RNA interference is a process in which a dsRNA directs homologous sequence-specific degradation of messenger RNA.
• RNAi can be triggered by 21 -nucleotide duplexes of small interfering RNA (siRNA) without activating the host interferon response.
• a dsRNA can be synthesized by methods known in the art. See, e.g., Caruthers et al., 1992, Methods in Enzymology 211, 3-19, Wincott et al., 1995,
• the dsRNA or vector as described above can be delivered to cancer cells by 5 methods, such as that described in Akhtar et al., 1992, Trends Cell Bio. 2, 139.
• it can be introduced into cells using liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, or bioadhesive microspheres.
• the dsRNA or vector can be locally delivered by direct injection or by use of an infusion pump.
• Other approaches include employing various transport and carrier systems, o for example through the use of conjugates and biodegradable polymers
• the above-described dsRNA contains a first strand that is complementary to CGCGGACTTGAGAGATCCTTT, or the complement thereof (e.g., siFUTl described in Example 2 below).
• the dsRNA contains a first strand that is complementary to CTATGTCCATGTCATGCCAAA, or5 the complement thereof (e.g., siFUT2 described in Example 2 below).
• conjugated means two entities are associated, preferably with sufficient affinity that the therapeutic benefit of the association between the two entities is realized.
• Conjugated includes covalent or noncovalent bonding as well as other forms of association, such as entrapment of one entitity on or within the other, or of either or both entities on or within a third entity (e.g., a micelle).
• the chaperone agent can be a naturally occurring substance, such as a protein (e.g., human serum albumin, low-density lipoprotein, or globulin), carbohydrate (e.g., 5 a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid), or lipid.
• a protein e.g., human serum albumin, low-density lipoprotein, or globulin
• carbohydrate e.g., 5 a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid
• a synthetic polyamino acid polymer e.g., polylysine, poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-
• the chaperone agent is a micelle, liposome, nanoparticle, or microsphere, in which the dsRNA or the DNA plasmid is encapsulated.
• a chaperone agent serves as a substrate for attachment of one or more of a fusogenic agent, a condensing agent, or a targeting agent.
• a fusogenic agent is responsive to the local pH. For instance, upon encountering the pH within an endosome, it can cause a physical change in its immediate environment (e.g., a change in osmotic properties, which disrupts or increases the permeability of the endosome membrane), thereby facilitating release of a dsRNA or DNA plasmid into host cell's cytoplasm.
• a preferred fusogenic agent o changes charge, for example, becoming protonated at a pH lower than a physiological range (e.g., at pH 4.5-6.5).
• Fusogenic agents can be molecules containing an amino group capable of undergoing a change of charge (e.g., protonation) when exposed to a specific pH range.
• Such fusogenic agents include polymers that contain polyamino chains (e.g., polyethyleneimine) and membrane disruptive agents (e.g., mellittin).5
• Other examples include polyhistidine, polyimidazole, polypyridine, polypropyleneimine, mellitin, and a polyacetal substance (e.g., a cationic polyacetal).
• a condensing agent interacts with (e.g., attracts, holds, or binds to) the dsRNA or the DNA plasmid and causes it to condense (e.g., reducing the size of the dsRNA/plasmid), thus protecting the dsRNA/plasmid against degradation.
• the condensing agent includes a moiety (e.g., a charged moiety) that interacts with the dsRNA or the DNA plasmid via, e.g., ionic interactions.
• condensing agent examples include a polylysine, spermine, spermidine, polyamine or quarternary salt thereof, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, 5 and an alpha helical peptide.
• Example 1 Induction of Antibodies Specific to Globo H and SSEA3 with KLH-conjugated Globo H and ⁇ -Galcer.
• Globo H-KLH was purchased from Optimer Pharmaceuticals. Three groups of 6-week-old female BALB/b mice (BioLASCO), two in each group, were injected (s.c.) with PBS ("control mice”), 0.6 ⁇ g KLH-Globo H ("Globo H mice”), and 0.6 ⁇ g 5 KLH-Globo H in combination with 2 ⁇ g ⁇ -GalCer (“Globo H-GalCer mice”), respectively, once every week for three weeks. Sera were collected from the mice of each group 10 days after the last injection and antibodies specific to Globo H and SSEA3 were detected following the method described in Huang et al., Proc, Natl. Acad. ScL USA 103 : 15-20 (2006).
• the sera were diluted 1 :25 with 3% o BSA/PBS buffer and 50 ml of each diluted serum were incubated with a slide, to which Globo H and S SE A3 were attached, in a humidifying chamber for 1 hour.
• the slide was washed three times with 0.05% PBS/Tween 20 (PBST) and subsequently incubated with 100 ⁇ l Cy5 -conjugated goat anti-mouse IgG antibody(l :200) in the same chamber. After being air-dried, the slide was washed5 with PBST and water, each for three times, and then measured for the levels of fluorescence released thereby with a microarray scanner (Gen ⁇ Pix 4000B; Molecular Devices). The results thus obtained were analyzed with the GenePix Pro software.
• Globo H mice In the Globo H mice, only a low level of anti-Globo H IgG antibody was detected and the level of anti-SSEA IgG antibody was undetectable. See Fig. 2. o Differently, the Globo H-GalCer mice showed high levels of both anti-Globo H and anti-SSEA3 IgG antibodies. See also Fig. 2. These findings indicated that Globo H-KLH in combination with ⁇ -GalCer is an effective vaccine for inducing both anti-Globo H and anti-SSEA3 antibodies.
• L-futl CCTGCCAGACTCTGAGTTCC and AGGCTTAGCCAATGTCCAGA as well as L-fut2:
• GGGAGTTACCGGTGCAGATA and R-fut2 GTCCC AGTGCCTTTGATGTT.
• the RT-PCR reaction was carried out under the following conditions: 50 0 C for 2 5 min, 95 0 C for 10 min, followed by 40 cycles of 95 0 C for 10 sec and 60 0 C for 1 min, using an ABI Prism 7000 Sequence Detection System and the results thus obtained were analyzed using the ABI Prism 7000 SDS software (Applied Biosystems) to obtain a threshold cycle number (Ct value) for the mRNA levels of FUTl and FUT2 in each cell line.
• the Ct value was normalized against the mRNA level of HPRTl in0 the same cell line to obtain a ⁇ Ct value.
• the ⁇ Ct value of FUTl in MCF-7 was used to normalize the ⁇ Ct value of either FUTl or FUT2 in each cell-line.
• the fold-change of a mRNA level was calculated based on the following formula:
• FUTl or FUT2 were reduced via RNA interference as follows. o Nucleotide sequences encoding siFUTl (containing a sequence complementary to CGCGGACTTGAGAGATCCTTT) and siFUT2 (containing a sequence complementary to CTA TGTCCATGTCATGCCAAA) were cloned into a VSV-G-pseudotype lentiviral vector and introduced into 293T cells together with packaging plasmids pMD.G and pCMV ⁇ R8.91. Lentiviral particles thus produced 5 were harvested at 48 and 72 hours after transfection and concentrated by ultracentrifugation (25,000 rpm, 90 minutes).
• virus particles capable of expressing siFUTl or siFUT2 were incubated with ThT-47D or MB 157 (plated at 2x10 5 cells /well in 6-well plates) in the presence of 8 ⁇ g/mL polybrene (Sigma- Aldrich Corp.). The cells were harvested 96 hours later and the mRNA o levels of FUTl and FUT2 were determined by quantitative RT-PCR as described above. As shown in Fig. 3, siFUTl successfully reduced the level of FUTl mRNA in MB 157 cells (see panel A). Similarly, siFUTl and siFUT2 reduced the levels of FUTl and FUT2 mRNAs, respectively, in T-47D cells. See Fig. 3, panel B.
• the levels of Globo H in both the MB 157 and the T-47D cells were determined via flow cytometry using the AlexaFluor488-VK-9 antibody as follows. Aliquots of cells, each containing IxIO 5 cells, were incubated first with anti-GloboH-Alexa488 (Vk9; see Chang et al, Proc. Natl. Acad. Sci. USA 105:11667-11672 (2008) for 1 hour on ice, then with biotinylated-UEAl (Vector Labotories) for one hour on ice, and finally with FITC-conjugated streptavidin (Jackson ImmunoResearch) for I hour on ice.
• MB 157 and T-47D cells infected with virus particles expressing siFUTl or siFUT2, were suspended in DMEM/F12 medium supplemented with 0.4% BSA, 5 20ng/ml EGF, 20ng/ml bFGF, 5ug/ml insulin, l ⁇ M hydrocortisone, 4 ⁇ g/ml heparin, Ix B27 supplement, and 1% methyl cellulose (Sigma- Aldrich)at a density of 1,000 cells/ml. The suspended cells were then seeded on ultra low attachment plates (Costar) and cultured under suitable conditions to allow mammosphere formation. The primary mammosphere thus formed were Cultures were fed weekly.
• o secondary mammosphere culture primary mammospheres were harvested, dispersed with trypsin (Gibco), pelleted, suspended in the culture medium described above at 1,000 cells/ml. The suspended cells were then cultured following the method described above to allow formation of secondary mammosphere.
• the numbers of mammopheres formed by both MB 157 and T-47D cells expressing siFUTl were only5 50% of that of the mammopheres formed by non-infected cells, indicating that siFUTl significantly reduced the mammophere formation capacity of the cancer cells.
• siFUT2 also significantly reduced the o mammophere formation capacity of cancer cells.
• balb/c nude mice and NOD/SCID mice were injected with 17- ⁇ -estradiol (1.7mg/ml) subcutaneously at the lateral side of each mouse.
• 8-week-old, female balb/c nude mice were injected at their mammory fat pad with (i) 5 MB 157 cells (1x10 7 ) stably expressing siFUT, (ii) vehicle control MB 157 cells
• T-47D cells (5x10 6 ) stably expressing siFUTl
• T-7D cells (5x10 6 ) stably expressing siFUT2
• vehicle control T-47D cells 5x10 6 ), all suspended in 0.1ml of 50% Matrigel (BD Biosciences) and 50% supplemented RPMI- 1640 medium.
• T-47D cells expressing0 both siFUTl and siFUT2 were small, round-shaped cells forming dense clusters. Similar morphology changes were observed in MB- 157 cells expressing siFUTl.
• ACEA's 96 microtiter plates were coated with fibronectin (25ug/ml, Sigma), type IV collagen (2ug/ml, BD biosciences), or5 laminin (5ug/ml, Sigma), all being diluted at appropriate folds in PBS, at 37 0 C for 1 hr and then blocked with 1 % BSA for 1 h at 37 0 C.
• MB 157 and T-47D cells were seeded at 2.5 xlO 4 per lOO ⁇ l of culture medium in the coated ACEA's 96 microtiter plates.
• MB 157 and T-47D cells were plated in a 12-well plate in a serum-containing medium until they reached 60% confluence. The cells were then infected with the virus particles described in Example 1 above or introduced with a control plasmid. These cells reached 100% confluence in a 2-day o culture period. The cells were then starved overnight and confluent monolayers of the cells were wounded with a 20ul plastic pipette tip sharply. After being washed with RPMI medium supplemented with serum, the cells were incubated in the RPMI medium and examined using a time-lapse microscope with temperature and CO 2 controls. Phase-contrast images of the cells were acquired every 4 h for 3 days or every 2h for 1 day.
• the rate of cell migration was determined using Metamorph 5 software that measures the distance that the cells have traveled during a desired time period.
• Results indicate that siFUTl suppressed migration of T-47D cells and MB 158 cells by 2.81 and 2.13, respectively, as compared with the cells trans fected with the control plasmid.
• Exogenous addition of Globo H-ceramide rescued the reduced migration capacity of cells expressing siFUTl or siFUT2. This data o indicates that the observed migration reduction was caused by the decreased level of

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Genetics & Genomics (AREA)
• Microbiology (AREA)
• Organic Chemistry (AREA)
• Oncology (AREA)
• Biomedical Technology (AREA)
• Immunology (AREA)
• Mycology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biotechnology (AREA)
• Wood Science & Technology (AREA)
• General Engineering & Computer Science (AREA)
• Zoology (AREA)
• Pregnancy & Childbirth (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Reproductive Health (AREA)
• Developmental Biology & Embryology (AREA)
• Gynecology & Obstetrics (AREA)
• Plant Pathology (AREA)
• Virology (AREA)
• Physics & Mathematics (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=41431519

Family Applications (2)

Family Applications After (1)

Country Status (11)

Cited By (12)

Families Citing this family (48)

Family Cites Families (26)

• 2009
  • 2009-06-16 CN CN2009801237219A patent/CN102065868A/zh active Pending
  • 2009-06-16 WO PCT/US2009/047537 patent/WO2010005735A2/en not_active Ceased
  • 2009-06-16 EP EP09794927A patent/EP2303286A4/en not_active Withdrawn
  • 2009-06-16 CA CA2728344A patent/CA2728344A1/en not_active Abandoned
  • 2009-06-16 US US12/485,546 patent/US20090317411A1/en not_active Abandoned
  • 2009-06-16 AU AU2009268937A patent/AU2009268937A1/en not_active Abandoned
  • 2009-06-16 KR KR1020117001004A patent/KR20110031949A/ko not_active Withdrawn
  • 2009-06-16 JP JP2011513760A patent/JP2011524375A/ja active Pending
  • 2009-08-06 MX MX2010013932A patent/MX2010013932A/es active IP Right Grant
  • 2009-08-06 EP EP09789075.0A patent/EP2310047B1/en active Active
  • 2009-08-06 US US12/537,129 patent/US8268969B2/en active Active
  • 2009-08-06 JP JP2011514633A patent/JP5628158B2/ja active Active
  • 2009-08-06 CA CA2728341A patent/CA2728341C/en active Active
  • 2009-08-06 MX MX2014004316A patent/MX350230B/es unknown
  • 2009-08-06 ES ES09789075T patent/ES2570630T3/es active Active
  • 2009-08-06 AU AU2009269127A patent/AU2009269127B2/en not_active Ceased
  • 2009-08-06 NZ NZ590140A patent/NZ590140A/en not_active IP Right Cessation
  • 2009-08-06 WO PCT/US2009/004519 patent/WO2010005598A1/en not_active Ceased
• 2012
  • 2012-08-07 US US13/568,510 patent/US9028836B2/en active Active
• 2014
  • 2014-02-26 JP JP2014035431A patent/JP5795655B2/ja active Active
• 2015
  • 2015-04-01 US US14/675,838 patent/US9603913B2/en active Active
  • 2015-08-11 JP JP2015159196A patent/JP6151319B2/ja active Active

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events